John Maggio
#181,423
Most Influential Person Now
American pharmacologist
John Maggio 's AcademicInfluence.com Rankings
John Maggio medical Degrees
Medical
#3760
World Rank
#4268
Historical Rank
Pharmacology
#491
World Rank
#550
Historical Rank
Download Badge
Medical
John Maggio 's Degrees
- Bachelors Pharmacology University of California, Berkeley
- PhD Pharmacology University of California, San Francisco
Why Is John Maggio Influential?
(Suggest an Edit or Addition)According to Wikipedia, John Edward Maggio was an American pharmacologist. He earned undergraduate and advanced degrees in chemistry from Harvard University. Maggio specialized in Alzheimer's disease and taught at the University of Cincinnati as Flor van Maanen Professor of Pharmacology and Experimental Therapeutics. He died in Hyde Park, Cincinnati, of cancer on 15 April 2017, aged 64.
John Maggio 's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Receptor endocytosis and dendrite reshaping in spinal neurons after somatosensory stimulation. (1995) (482)
- Aluminum, Iron, and Zinc Ions Promote Aggregation of Physiological Concentrations of β‐Amyloid Peptide (1993) (449)
- Fibrillar β-Amyloid Induces Microglial Phagocytosis, Expression of Inducible Nitric Oxide Synthase, and Loss of a Select Population of Neurons in the Rat CNS In Vivo (1998) (366)
- Purification and characterization of chlorotoxin, a chloride channel ligand from the venom of the scorpion. (1993) (350)
- Alzheimer's disease amyloid propagation by a template-dependent dock-lock mechanism. (2000) (346)
- The Alzheimer's peptide a beta adopts a collapsed coil structure in water. (2000) (316)
- Amyloid β-Peptide Is Transported on Lipoproteins and Albumin in Human Plasma* (1996) (312)
- Rapid endocytosis of a G protein-coupled receptor: substance P evoked internalization of its receptor in the rat striatum in vivo. (1995) (297)
- Synaptic relationship between substance P and the substance P receptor: light and electron microscopic characterization of the mismatch between neuropeptides and their receptors. (1994) (287)
- Receptor binding sites for substance P, but not substance K or neuromedin K, are expressed in high concentrations by arterioles, venules, and lymph nodules in surgical specimens obtained from patients with ulcerative colitis and Crohn disease. (1988) (283)
- Morphological characterization of substance P receptor‐immunoreactive neurons in the rat spinal cord and trigeminal nucleus caudalis (1995) (239)
- Substance P receptors: Localization by light microscopic autoradiography in rat brain using [3H]SP as the radioligand (1984) (223)
- Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide. (1992) (193)
- Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red. (1998) (192)
- Point Substitution in the Central Hydrophobic Cluster of a Human β-Amyloid Congener Disrupts Peptide Folding and Abolishes Plaque Competence† (1996) (159)
- Intestinal absorption and excretion of octapeptides composed of D amino acids. (1994) (145)
- Differential expression of substance P receptors in patients with Crohn's disease and ulcerative colitis. (1995) (139)
- Receptors for sensory neuropeptides in human inflammatory diseases: Implications for the effector role of sensory neurons (1989) (139)
- Novel peptide fragments originating from PGLa and the caerulein and xenopsin precursors from Xenopus laevis. (1986) (132)
- Deposition of monomeric, not oligomeric, Abeta mediates growth of Alzheimer's disease amyloid plaques in human brain preparations. (1999) (125)
- Zinc‐Induced Aggregation of Human and Rat β‐Amyloid Peptides In Vitro (1996) (116)
- Substance P receptor binding sites are expressed by glia in vivo after neuronal injury. (1989) (113)
- The autoradiographic distribution of kassinin and substance K binding sites is different from the distribution of substance P binding sites in rat brain. (1984) (111)
- Regional distribution of kassinin-like immunoreactivity in rat central and peripheral tissues and the effect of capsaicin (1984) (110)
- In vitro growth of Alzheimer's disease beta-amyloid plaques displays first-order kinetics. (1996) (109)
- Receptor binding sites for substance P and substance K in the canine gastrointestinal tract and their possible role in inflammatory bowel disease (1988) (105)
- The localization of sensory nerve fibers and receptor binding sites for sensory neuropeptides in canine mesenteric lymph nodes (1988) (100)
- Pharmacological analysis of [3H]‐senktide binding to NK3 tachykinin receptors in guinea‐pig ileum longitudinal muscle‐myenteric plexus and cerebral cortex membranes (1990) (93)
- Secreted Amyloid β-Proteins in a Cell Culture Model Include N-Terminally Extended Peptides That Impair Synaptic Plasticity (2014) (88)
- Local Anesthetics Inhibit Substance P Binding and Evoked Increases in Intracellular Calcium sup 2+ (1995) (84)
- Expression of Endothelin-B Receptors by Gliain VivoIs Increased after CNS Injury in Rats, Rabbits, and Humans (1997) (84)
- Local anesthetics inhibit substance P binding and evoked increases in intracellular Ca2+. (1995) (81)
- Endothelin receptor expression in the normal and injured spinal cord: potential involvement in injury-induced ischemia and gliosis (2003) (81)
- Phosphoproteome Analysis of Cardiomyocytes Subjected to &bgr;-Adrenergic Stimulation: Identification and Characterization of a Cardiac Heat Shock Protein p20 (2004) (80)
- Delayed behavioral effects following intrahippocampal injection of aggregated Aβ(1–42) (1999) (80)
- Substance K and substance P differentially modulate mesolimbic and mesocortical systems (1985) (76)
- Mapping Peptide-binding Domains of the Substance P (NK-1) Receptor from P388D Cells with Photolabile Agonists (*) (1995) (76)
- Substance P and substance K receptor binding sites in the human gastrointestinal tract: Localization by autoradiography (1988) (70)
- The localization and characterization of substance P and substance K in striatonigral neurons (1986) (70)
- Synthesis of the first topologically non-planar molecule (1981) (69)
- Endogenous opioids inhibit early-stage pancreatic pain in a mouse model of pancreatic cancer. (2006) (63)
- Intra-arterial infusion of [125I]A beta 1-40 labels amyloid deposits in the aged primate brain in vivo. (1996) (59)
- Substance K and substance P in the ventral tegmental area (1985) (57)
- Differential expression of two isoforms of the neurokinin-1 (substance P) receptor in vivo (1996) (56)
- Activation barriers to structural transition determine deposition rates of Alzheimer's disease a beta amyloid. (2000) (55)
- Pharmacological characterisation of a novel tachykinin isolated from mammalian spinal cord. (1984) (55)
- Proteomic analysis of the reactive phenotype of astrocytes following endothelin‐1 exposure (2003) (52)
- Substance P binding sites on intestinal lymphoid aggregates and blood vessels in inflammatory bowel disease correspond to authentic NK-1 receptors (1994) (49)
- Absorption and excretion of undegradable peptides: role of lipid solubility and net charge. (1997) (49)
- A novel radioimmunoassay for neuromedin K. I. Absence of neuromedin K-like immunoreactivity in guinea pig ileum and urinary bladder. II. Heterogeneity of tachykinins in guinea pig tissues (1989) (43)
- Zinc and Alzheimer's disease. (1995) (42)
- Point substitution in the central hydrophobic cluster of a human beta-amyloid congener disrupts peptide folding and abolishes plaque competence. (1996) (41)
- A pharmacological study with substance K: evidence for multiple types of tachykinin receptors. (1984) (40)
- Moenomycin a: Minimum structural requirements for biological activity (1987) (39)
- Immunocytochemical localization of neuromedin K (neurokinin B) in rat spinal ganglia and cord (1991) (39)
- Heterogeneity of tachykinin-like immunoreactive peptides in rat spinal cord and dorsal root ganglia (1989) (38)
- Receptor binding sites for cholecystokinin, galanin, somatostatin, substance P and vasoactive intestinal polypeptide in sympathetic ganglia (1992) (37)
- Photoaffinity cross-linking of Alzheimer's disease amyloid fibrils reveals interstrand contact regions between assembled beta-amyloid peptide subunits. (2001) (36)
- “Kassinin” in mammals: The newest tachykinins (1985) (36)
- Zinc-induced aggregation of human and rat beta-amyloid peptides in vitro. (1996) (35)
- Stereochemical specificity of Alzheimer's disease β-peptide assembly (1999) (34)
- Increased substance P receptor expression by blood vessels and lymphoid aggregates inClostridium difficile-induced pseudomembranous colitis (1996) (34)
- Alterations in receptors for sensory neuropeptides in human inflammatory bowel disease. (1991) (33)
- Proteomic analysis of hyperdynamic mouse hearts with enhanced sarcoplasmic reticulum calcium cycling (2004) (32)
- Rearrangement of a geometrically restricted triepoxide to the first topologically nonplanar molecule: a reaction path elucidated by using oxygen isotope effects on carbon-13 chemical shifts (1981) (31)
- Moenomycin A: further structural studies and preparation of simple derivatives (1983) (31)
- Lack of β-Amyloidosis in transgenic mice expressing low levels of familial Alzheimer's disease missense mutations (1996) (26)
- Agonist-induced photoincorporation of a p-benzoylphenylalanine derivative of substance P into membrane-spanning region 2 of the Torpedo nicotinic acetylcholine receptor delta subunit. (1994) (25)
- Neuropeptide Y/peptide YY receptor binding sites in the heart: Localization and pharmacological characterization (1993) (25)
- Structure of a mycobacterial polysaccharide-fatty acyl-CoA complex: nuclear magnetic resonance studies. (1980) (21)
- Simultaneous extraction of total RNA and peptides from tissues: Application to tachykinins (1995) (21)
- Deposition of soluble amyloid-beta onto amyloid templates: with application for the identification of amyloid fibril extension inhibitors. (1999) (20)
- A beta deposition inhibitor screen using synthetic amyloid. (1997) (20)
- New insights into the neuropathology and cell biology of Alzheimer's disease. (1997) (20)
- Noninvasive imaging of peripherally injected Alzheimer's disease type synthetic A beta amyloid in vivo. (2002) (18)
- p-(4-Hydroxybenzoyl)phenylalanine: a photoreactive amino acid analog amenable to radioiodination for elucidation of peptide-protein interaction. Application to substance P receptor. (1997) (18)
- Neural system-enriched gene expression: relationship to biological pathways and neurological diseases. (2004) (18)
- History of Tachykinin Peptides (1994) (16)
- Trispiro[tricyclo[3.3.3.01,5]undecane-2,1.8,1":9,1'"-tris[cyclopropane]] a chiral fluxional hydrocarbon (1981) (16)
- A novel hexacyclic ring system from glycoluril (1985) (16)
- Development of a novel probe for measuring drug binding to the F1*S variant of human alpha 1-acid glycoprotein. (2001) (14)
- Stereochemical specificity of Alzheimer's disease beta-peptide assembly. (1999) (11)
- Radioimmunoassay of Tachykinins (1991) (11)
- Aβ deposition inhibitor screen using synthetic amyloid (1997) (10)
- Apolipoprotein E affects amyloid formation but not amyloid growth in vitro: Mechanistic implications for ApoE4 enhanced amyloid burden and risk for Alzheimer's disease (2002) (10)
- Localization of bombesin receptors in human gastrointestinal tract using quantitative receptor autoradiography (1987) (8)
- Receptor Involvement in Pathology and Disease (1994) (8)
- The regional distribution of kassinin-like immunoreactivity in central and peripheral tissues of the cat (1985) (8)
- Erratum to “endothelin receptor expression in the normal and injured spinal cord: potential involvement in injury-induced ischemia and gliosis” [Exp. Neurol. 180 (2003) 1–13]☆ (2003) (8)
- Evidence for vasoactive intestinal polypeptide as a neurotransmitter in smooth muscle of the urogenital tract (1984) (7)
- Assays for Substance P and Tachykinin Receptors (1991) (3)
- Neurobiology of Alzheimer's disease pathology (1997) (3)
- Heterogeneity of Central and Peripheral Tachykinin Binding Sites (1987) (2)
- Protein folding intermediates and Alzheimer’s disease (1999) (2)
- Substance P: Inactivation in CNS, Enzymatically Resistant Analogue and Development of "Brain Selective" Agonist (1983) (2)
- 762 Aβ is transported on lipoproteins and albumin in human biological fluids (1996) (1)
- Immunization against AB in APP overexpressing mice (2000) (1)
- UV light absorption parameters of the pathobiologically implicated bilirubin oxidation products, MVM, BOX A, and BOX B (2018) (1)
- Moenomycin A: Minimum Structural Requirements for Biological Activity. (1987) (1)
- ALZHEIMER'S DISEASE AMYLOID-BETA PEPTIDE (RESIDUES 10-35) (2001) (0)
- SYNTHESIS OF THE FIRST TOPOLOGICALLY NONPLANAR MOLECULE (1981) (0)
- Distribution, stability and ultimate fate of aggregated B-amyloid injected into the rat brain (1995) (0)
- Biochemical Pharmacology of Substance P Receptors (1984) (0)
- 528 Forces in the formation of amyloid deposits (1996) (0)
- Safety Pharmacology Master of Science (MS) program: design and implementation (2012) (0)
- Behavioural and CNS response to aggregated AB injections in rats (1997) (0)
- Behavioural deficits and CNS changes in the APP-overexpressing mouse (1999) (0)
- 2-D mapping of phosphoproteins in mouse cardiomyocytes in response to β-agonists (2001) (0)
- Development of a professional science master's degree program in safety pharmacology (2011) (0)
- New Master of Science program emphasizing Safety Pharmacology—Results to date (2015) (0)
This paper list is powered by the following services:
Other Resources About John Maggio
What Schools Are Affiliated With John Maggio ?
John Maggio is affiliated with the following schools:
